| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.JU.0000137844.77524.97 |
| P698 | PubMed publication ID | 15371885 |
| P2093 | author name string | Michael B Chancellor | |
| Chao-Cheng Huang | |||
| Po-Hui Chiang | |||
| Yao-Chi Chuang | |||
| Naoki Yoshimura | |||
| P433 | issue | 4 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1529-1532 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats | |
| P478 | volume | 172 |
| Q43648074 | A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome |
| Q35178189 | Acid-sensitive ion channels and receptors |
| Q48227598 | Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). |
| Q37114371 | Advances in intravesical therapy for urinary tract disorders |
| Q36576020 | Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms |
| Q26744717 | Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis |
| Q37801072 | Botulinum Toxin Therapy for Neurogenic Detrusor Overactivity |
| Q52609601 | Botulinum Toxin Type A-A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions. |
| Q37954278 | Botulinum neurotoxin for pain management: insights from animal models |
| Q26764765 | Botulinum toxin A for the Treatment of Overactive Bladder |
| Q28194984 | Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations |
| Q51458905 | Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. |
| Q36872297 | Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going |
| Q34625231 | Botulinum toxin in the treatment of overactive bladder |
| Q38008697 | Botulinum toxin injection for lower urinary tract dysfunction |
| Q36815354 | Botulinum toxin injection: a review of injection principles and protocols |
| Q37973408 | Botulinum toxin type A for the treatment of lower urinary tract disorders |
| Q36488226 | Botulinum toxin type A for the treatment of migraine |
| Q81362098 | Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates |
| Q36329632 | Botulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladder |
| Q46151377 | Botulinum toxin type A-induced changes in the chemical coding of dorsal root ganglion neurons supplying the porcine urinary bladder |
| Q80514317 | Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up |
| Q38249927 | Brain-derived neurotrophic factor in urinary continence and incontinence. |
| Q90226597 | Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? |
| Q39026796 | Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. |
| Q48249412 | Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial |
| Q89566652 | Complete reversal of the clinical symptoms and image morphology of ketamine cystitis after intravesical hyaluronic acid instillation: A case report |
| Q64332501 | Current best practice management of interstitial cystitis/bladder pain syndrome |
| Q35057523 | Drug Insight: biological effects of botulinum toxin A in the lower urinary tract |
| Q89578185 | Effect of Botulinum Toxin A on Bladder Pain-Molecular Evidence and Animal Studies |
| Q46670656 | Effect of eviprostat on bladder overactivity in an experimental cystitis rat model |
| Q90539502 | Efficacy and Safety of Noninvasive Intravesical Instillation of Onabotulinum Toxin-A for Overactive Bladder and Interstitial Cystitis/Bladder Pain Syndrome: Systematic Review and Meta-analysis |
| Q36006813 | Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis |
| Q33295359 | Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. |
| Q36844148 | Future aspects of botulinum neurotoxins |
| Q36946062 | Hitting below the belt (bladder): botulinum treatment of urethral and prostate disorders |
| Q35545750 | Integrative control of the lower urinary tract: preclinical perspective |
| Q28075595 | Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality |
| Q42160984 | Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement. |
| Q36034077 | Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach |
| Q66829551 | Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis |
| Q38075592 | Intravesical drug delivery for dysfunctional bladder |
| Q41478422 | Intravesical injection of botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome: 10 years of experience at a single center in China |
| Q51558644 | Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. |
| Q21284684 | Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome |
| Q26773571 | Intravesical liposome drug delivery and IC/BPS |
| Q39160922 | Intravesical liposome therapy for interstitial cystitis |
| Q38759710 | Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). |
| Q34914275 | Japanese guideline for diagnosis and treatment of interstitial cystitis |
| Q36226899 | Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome |
| Q38227058 | Neural control of lower urinary tract and targets for pharmacological therapy |
| Q36566845 | Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents |
| Q38551294 | New intraprostatic injectables and prostatic urethral lift for male LUTS. |
| Q38406085 | Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014). |
| Q35996597 | O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome |
| Q34890902 | Phoenixin: a novel peptide in rodent sensory ganglia |
| Q27013111 | Possible pathophysiology of ketamine-related cystitis and associated treatment strategies |
| Q26752959 | Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction |
| Q38210146 | Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis |
| Q90720476 | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
| Q39229232 | Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome |
| Q52340820 | Role of neurogenic inflammation in local communication in the visceral mucosa. |
| Q50144688 | Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-Based Slow Release Delivery System in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Pilot Study |
| Q37828392 | State of the art in intravesical therapy for lower urinary tract symptoms. |
| Q39346432 | Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia |
| Q33758307 | TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis |
| Q37538596 | Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery |
| Q36317549 | The effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint |
| Q37023861 | The pharmacological challenge to tame the transient receptor potential vanilloid-1 (TRPV1) nocisensor |
| Q44343810 | The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. |
| Q37103157 | The use of botulinum neurotoxin type A (BoNTA) in urology |
| Q52566035 | Therapeutic Approaches of Botulinum Toxin in Gynecology. |
| Q90394415 | Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside |
| Q46077661 | Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy |
| Q26773579 | Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients? |
| Q36292405 | Urologic applications of botox |
| Q88591208 | [Minimally invasive treatment of benign prostatic hyperplasia] |
| Q79836645 | [Potential antinociceptive mechanisms of botulinum toxin] |
| Q79990241 | [Sensory innervation of the bladder: clinical and therapeutic implications] |
Search more.